Literature DB >> 32048731

Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma.

Ann S LaCasce1, R Gregory Bociek2, Ahmed Sawas3, Paolo Caimi4, Edward Agura5, Jeffrey Matous6, Stephen M Ansell7, Howland E Crosswell8, Miguel Islas-Ohlmayer9, Caroline Behler10, Eric Cheung11, Andres Forero-Torres12, Julie Vose2, Owen A O'Connor3, Neil Josephson13, Yinghui Wang13, Ranjana Advani14.   

Abstract

Entities:  

Keywords:  Hodgkin lymphoma; autologous stem cell transplantation; bendamustine; brentuximab vedotin; first salvage therapy

Mesh：

Substances：

Year:  2020        PMID： 32048731     DOI： 10.1111/bjh.16499

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  8 in total

Review 1.  Efficacy of Brentuximab Vedotin and Nivolumab in Refractory or Relapsed Hodgkin Lymphoma: A Systematic Review.

Authors:  Sharina C Macapagal; Hayoung Lee; Javaria Abdul Jabbar; Anna Caroline Fjorden; Irene Tresa Joseph; Ramanpreet Kaur; Jihan A Mostafa
Journal:  Cureus       Date:  2022-03-24

Review 2.  Brentuximab-Induced Peripheral Neurotoxicity: A Multidisciplinary Approach to Manage an Emerging Challenge in Hodgkin Lymphoma Therapy.

Authors:  Roser Velasco; Eva Domingo-Domenech; Anna Sureda
Journal:  Cancers (Basel)       Date:  2021-12-05       Impact factor: 6.639

3.  Relapsed Refractory Hodgkin Lymphoma and Brentuximab Vedotin-Bendamustine Combination Therapy as a Bridge to Transplantation: Real-World Evidence From a Middle-Income Setting and Literature Review.

Authors:  Vivek S Radhakrishnan; Rajat Bajaj; Vasundhara Raina; Jeevan Kumar; Saurabh J Bhave; Reghu K Sukumaran Nair; Arijit Nag; Indu Arun; Lateef Zameer; Debdeep Dey; Neeraj Arora; Mayur Parihar; Jayanta Das; Rimpa B Achari; Deepak K Mishra; Mammen Chandy; Reena Nair
Journal:  Front Oncol       Date:  2022-01-21       Impact factor: 6.244

Review 4.  Autologous Stem Cell Transplantation in Hodgkin Lymphoma-Latest Advances in the Era of Novel Therapies.

Authors:  Yazeed Samara; Matthew Mei
Journal:  Cancers (Basel)       Date:  2022-03-29       Impact factor: 6.639

Review 5.  Bendamustine: A review of pharmacology, clinical use and immunological effects (Review).

Authors:  Hrvoje Lalic; Igor Aurer; Drago Batinic; Dora Visnjic; Tomislav Smoljo; Antonija Babic
Journal:  Oncol Rep       Date:  2022-05-04       Impact factor: 4.136

Review 6.  Novel Salvage Therapy Options for Initial Treatment of Relapsed/Refractory Classical Hodgkin's Lymphoma: So Many Options, How to Choose?

Authors:  Radhika Takiar; Yasmin Karimi
Journal:  Cancers (Basel)       Date:  2022-07-20       Impact factor: 6.575

7.  LAG-3 is expressed on a majority of tumor infiltrating lymphocytes in pediatric Hodgkin lymphoma.

Authors:  Scott Moerdler; Michelle Ewart; Debra L Friedman; Kara Kelly; Qinglin Pei; Mou Peng; XingXing Zang; Peter D Cole
Journal:  Leuk Lymphoma       Date:  2020-10-28

8.  Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.

Authors:  Ryan C Lynch; Ryan D Cassaday; Stephen D Smith; Jonathan R Fromm; Andrew J Cowan; Edus H Warren; Mazyar S Shadman; Andrei Shustov; Brian G Till; Chaitra S Ujjani; Edward N Libby; Mary Philip; Hilary Coye; Christen N Martino; Sandra L Bhark; Karolyn Morris; Heather Rasmussen; Sanaz Behnia; Jenna Voutsinas; Ajay K Gopal
Journal:  Lancet Haematol       Date:  2021-08       Impact factor: 30.153
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.